Respiratory syncytial virus vaccine mRNA lipid nanoparticles pattern
determined via bioinformatics
Abstract
Background: RSV, or respiratory syncytial virus, is a
deadly condition that is present all over the world today. Without
systemic transmission, the infection is initially contained to the lower
respiratory tract. The objective of the study: Bioinformatics
was used in Egypt to create an mRNA vaccine against the
Respiratory syncytial virus (RSV). Methodology: In the
present screening experimental study, lipid nanoparticles vaccine of
mRNA of surface fusion protein of Respiratory syncytial
virus was manufactured. The present vaccine delivery system was lipid
nanoparticles with particle size approximately 90 nanometre which were
manufactured by hot micro-emulsion method. In stages 1 and 2 of clinical
trials, the immunogenicity of the current mRNA RSV vaccine was
evaluated. Results: The current vaccine demonstrated 81%
immunogenicity in animal testing, but only 69% in stages 1 and 2 of
clinical trials. Its side effects were manageable. The results persisted
for a while. In the current trial, the vaccination proved effective as a
preventative measure against RSV infection. The current
vaccination lacked antibody-dependent enhancement, which causes
non-protective antibodies to develop. These non neutralizing antibodies
exacerbate infection by the activation of cytokines and complement
cascade through the formation of immune complexes or enhancement of the
virus entry and replication in the host cells. On the other hand, the
current RSV mRNA vaccine of the surface fusion protein consequent
on production of powerful neutralizing antibodies with prolonged
immunity especially to infants and elderly candidates whom received the
optimal dosage regimen.